NEW YORK, Dec. 14, 2023 (GLOBE NEWSWIRE) Pomerantz LLP is investigating claims on behalf of investors of Legend Biotech Corporation (“Legend” or the “Company”) (NASDAQ: LEGN). Such investors are
In CARTITUDE-4, CARVYKTI® demonstrated clinically meaningful improvements in patient-reported outcomes when compared to standard of careThe as-treated population in CARTITUDE-4 demonstrated strong rates of progression-free survival and overall responseLonger-term data from CARTITUDE-2 showed deep and durable respons.